Staten Biotechnology B.V. aims to develop novel and innovative strategies for the treatment of dyslipidaemia, with a focus on hypertriglyceridemia treatment. BioGeneration Ventures (BGV) provided the company's seed financing in 2014 and Forbion led the Series A round, as the sole new investor. Staten is a prime example of Forbion's and BGV's company building activities, growing great scientific ideas into promising companies.
View Top Employees from Staten BiotechnologyWebsite | http://www.statenbiotech.com |
Revenue | $5 million |
Employees | 1 (1 on RocketReach) |
Founded | 2014 |
Address | Transistorweg 5J, Nijmegen, Gelderland, NL |
Phone | +31 35 760 6500 |
Industry | Biotechnology, Business Services General, Business Services, Science and Engineering, Drug Discovery, Therapeutics, Health Care |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies |
Looking for a particular Staten Biotechnology employee's phone or email?
The Staten Biotechnology annual revenue was $5 million in 2024.
Patrick Round is the Medical Director of Staten Biotechnology.
1 people are employed at Staten Biotechnology.
Staten Biotechnology is based in Nijmegen, Gelderland.
The NAICS codes for Staten Biotechnology are [541, 54171, 54, 541713, 5417].
The SIC codes for Staten Biotechnology are [87, 873].